Table 1.
Characteristics of the 108 patients with SLE treated for HTN, controlled versus uncontrolled HTN (>130/80 mm Hg)
| Variables | All patients N=108 |
Controlled, N=36 |
Uncontrolled, N=72 |
Differences (95% CI)* |
| Male sex, N (%) | 18 (16.7) | 6 (16.7) | 12 (16.7) | <0.01 (−0.17 to 0.14) |
| Caucasian race/ethnicity, N (%) | 71 (65.7) | 19 (52.8) | 52 (72.2) | 0.19 (0.00 to 0.38) |
| Age at last visit >65 years, N (%) | 45 (41.7) | 12 (33.3) | 33 (45.8) | 0.12 (−0.07 to 0.30) |
| Mean body mass index, (SD) | 26.6 (5.2) | 25.6 (5.1) | 27.1 (5.2) | 2.04 (−0.42 to 4.17) |
| Mean SLE duration, years (SD) | 23.5 (14.2) | 23.1 (15.2) | 23.7 (13.8) | 0.94 (−5.01 to 6.96) |
| SLEDAI-2K ≥4, N (%) | 48 (44.4) | 18 (50.0) | 30 (41.7) | 0.08 (−0.11 to 0.27) |
| Renal damage ≥1, N (%) | 32 (29.6) | 16 (44.4) | 16 (22.2) | 0.22 (0.04 to 0.40) |
| Prednisone use, N (%) | 16 (14.8) | 5 (13.9) | 11 (15.3) | 0.01 (−0.15 to 0.14) |
| NSAIDs use, N (%) | 5 (4.6) | 1 (2.8) | 4 (5.6) | 0.03 (−0.09 to 0.11) |
| Using >1 BP medication, N (%) | 38 (35.2) | 10 (27.8) | 28 (38.9) | 0.11 (−0.08 to 0.28) |
| Mean systolic BP, (SD) | 134.2 (18.2) | 116.0 (9.4) | 143.2 (14.3) | 26.0 (21.0 to 31.0) |
| Mean diastolic BP, (SD) | 79.9 (10.8) | 70.7 (6.3) | 84.6 (9.5) | 13.0 (10.0 to 16.0) |
*The difference in proportions between groups (controlled (n=36) and uncontrolled (n=72)) as well as their 95% CIs. This analysis was performed using the Newcombe-Wilson score method. For continuous variables (body mass index, SLE duration, systolic BP and diastolic BP), we used the Wilcoxon test to determine the CIs for the difference.
BP, blood pressure; HTN, hypertension; NSAIDs, non-steroidal anti-inflammatory drugs; SLE, systemic lupus erythematosus; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.